ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy

ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27 in Kumamoto, Japan. This prestigious event brought together leading experts from around the world to discuss cutting-edge developments in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the highlights of this year’s meeting was the “Sino-Japanese Joint Symposium on Stem Cells and Cellular Therapy,” co-organized by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), and Kumamoto University, marking the successful restart of the Sino-Japanese academic exchange mechanism. During the conference, Oncology Frontier – Hematology Frontier invited Professor Tao Cheng of the Institute of Hematology & Blood Diseases Hospital to share his insights on the origins of this joint symposium, the hottest frontiers in the field, and opportunities for young researchers to engage internationally.
ISEH 2025 China–Japan Dialogue | Prof. Jianxiang Wang and Prof. Naoki Hosen: Direct Insights into CAR-T Therapy for Leukemia and a New Blueprint for International Collaboration 

ISEH 2025 China–Japan Dialogue | Prof. Jianxiang Wang and Prof. Naoki Hosen: Direct Insights into CAR-T Therapy for Leukemia and a New Blueprint for International Collaboration 

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held in Kumamoto, Japan, from September 24–27. The conference brought together leading experts in hematology from around the world to discuss cutting-edge progress in basic hematology, immunology, stem cell research, and cell and gene therapies. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Professor Naoki Hosen from Osaka University for a deep dialogue on the latest advances in CAR-T therapy for leukemia. Their discussion covered multiple dimensions — from basic mechanisms and clinical applications to efficacy optimization and future directions — with the shared goal of promoting innovation in CAR-T therapy, advancing international collaboration, and improving global patient access and outcomes.
ISEH 2025 | Professor Xue Feng: AAV Vector Gene Therapy Driving Innovation in Hemophilia B Treatment in China

ISEH 2025 | Professor Xue Feng: AAV Vector Gene Therapy Driving Innovation in Hemophilia B Treatment in China

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held in Kumamoto, Japan, from September 24 to 27. The event brought together leading global experts to discuss cutting-edge advances in basic hematology, immunology, stem cell biology, and cellular and gene therapies. One of the highlights of the meeting was the China–Japan Joint Symposium on Stem Cell and Cell Therapy, which drew significant attention. Professor Xue Feng from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), delivered an insightful presentation titled “Adeno-Associated Virus Vector Expressing Factor IX Padua in Treating Hemophilia B in China.” Following the presentation, Oncology Frontier – Hematology Frontier conducted an exclusive interview with Professor Xue to explore this innovative approach and its future clinical prospects.